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65 Modeling of the whole CFTR 3D structure and its conformational
transitions
J.P. Mornon1, P. Lehn2, I. Callebaut1. 1IMPMC, UMR7590, CNRS, Universite´s
Paris6 et Paris7, Paris, France; 2U613, INSERM, Universite´ de Bretagne
Occidentale, Brest, France
The experimental 3D structure of the bacterial Sav1866 protein has provided
invaluable insights into the structural basis underlying the function of ATP-Binding
Cassette (ABC) exporters. Using this structure, we recently modeled the structure of
the membrane-spanning domains (MSD1/MSD2) and nucleotide-binding domains
(NBD1/NBD2) of human CFTR, in an ATP-bound, outward-facing conformation
(Cell Mol Life Sci 2008 65:2594–612). This modeling, based on the use of sensitive
methods allowing accurate alignments in the MSDs at high level of sequence
divergence, highlighted the crucial roles of some amino acids within the MSDs
(for substrate translocation) and at the interface between the MSDs and NBDs
(coupling interfaces).
We next modeled the inward-facing conformation of human CFTR, based on the
more recent corrected structures of the bacterial ABC lipid ﬂippase MsbA.
This modeling provides a framework to understand the probable conformational
transition between the inward- and outward-facing conformations, involving a
large conformational rearrangement within the MSDs and an evolution of NBDs
from a close conformation, in which the P-loops face each other, towards a
tight interface, with the nucleotide being sandwiched between the P-loop and the
signature sequence. Noteworthy is that the coupling interfaces between MSDs and
NBDs are largely maintained, supporting their crucial role as constant pivots and
highlighting the importance of F508 in this context.
In addition, we also constructed a two-segment model of the regulatory R domain.
The so-deduced model of the whole MSDs:NBDs:R assembly is supported by the
recent 3D reconstruction of CFTR from negatively stained electron microscopy
images.
Supported by: Vaincre La Mucoviscidose.
66 Reﬁnement of CFTR transmembrane segments by a novel
prediction tool
D. Paulet1, M. Claustres1,2, C. Be´roud1,2. 1Universite´ Montpellier1, Montpellier,
France; 2INSERM U827, Montpellier, France
CFTR is an ATP-binding cassette transporter and respect the general topology
of this super-family, which consists on two transmembrane domains (TMD) and
two nucleotide-binding domains, plus a unique R domain. The two TMDs are
both constituted of six transmembrane segments (TMS). They compose the CFTR
pore, which allows ionic movements, assuming the main role of CFTR. The global
topology of CFTR is well known, but these segments are roughly deﬁned; their
exact borders are still to be determined. Conduction and selectivity of CFTR pore
is crucial for its main function and some severe mutations have already been found
in TMD (p.Gly85Glu, p.Arg347Pro. . . ). Better deﬁnition of the amino acids of TMS
is obviously linked to an improvement in prediction of pathogenicity of sequence
variations.
Crystallization of CFTR should provide crucial information on its structure and
therefore on its mechanism. Due to CFTR high complexity and technical limitations,
crystallization of its TMDs has not been achieved yet. To circumvent these
restrictions, a great number of TMS prediction tools have been developed, but their
predictions for CFTR do not exactly match; they generally agree on a hydrophobic
core of a dozen of amino acids, which only represents about one half of a TMS.
We developed a bioinformatics tool for TMS and transmembrane secondary struc-
ture reﬁnement based on a new process on hydrophobic data. We validated our tool
on a set of well-deﬁned channels such as glycerol-3-phosphate transporter. We will
use this tool to improve knowledge on CFTR TMD and detect structural crucial
amino acids. As soon as data from expert laboratories are collected, cured and
integrated in the UMD-CFTRbase, results from our tool are expected to enhance
UMD-CFTRbase predictions of sequence variations.
Supported by: VLM.
67* Rescue of CF airway epithelial cell function in vitro by a CFTR
potentiator, VX-770
F. Van Goor1, B. Burton1, S. Hadida1, P. Grootenhuis1, E.R. Olson2, J. Wine3,
R. Frizzell4, M.A. Ashlock5, P. Negulescu1. 1Vertex Pharmaceuticals, San Diego,
CA, USA; 2Vertex Pharmaceuticals, Cambridge, MA, USA; 3Stanford University,
Stanford, CA, USA; 4University of Pittsburgh, Pittsburgh, PA, USA; 5Cystic
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Cystic ﬁbrosis (CF) is a fatal genetic disease caused by mutations in the gene
encoding CFTR, a PKA-gated Cl− channel that regulates salt and ﬂuid transport in
epithelial tissues. In the lung, mutations that decrease CFTR-mediated Cl− secretion
result in increased Na+ absorption through the epithelial Na+ channel, ENaC. These
abnormalities in salt transport are thought to dehydrate the airway surface, resulting
in the deleterious cascade of mucus accumulation, infection, and inﬂammation
that causes progressive lung damage. A therapeutic strategy for CF is to restore
defective CFTR-mediated Cl− secretion. A central question of this approach is
whether pharmacological modulation of CFTR can restore the downstream defects
in Na+ and ﬂuid transport sufﬁciently to promote mucociliary clearance. In these
in vitro studies, we demonstrate that VX-770, a CFTR potentiator in clinical
development to treat CF, increased Cl− secretion in cultures of human bronchial
epithelia (HBE) isolated from the airway of a subject with CF carrying the G551D
and F508del CFTR mutations. The level of G551D/F508del-CFTR-mediated Cl−
secretion in the presence of VX-770 was sufﬁcient to decrease the excessive Na+
and ﬂuid absorption and increase cilia beating. These data support the hypothesis
that increasing CFTR-mediated Cl− secretion with a small molecule may have
pleiotropic effects on epithelial cell function in patients with CF who carry the
G551D mutation.
Supported by: CFFT, Vertex Pharmaceuticals.
68* Rescue of A455E CFTR by temperature, small molecule correctors
and transcomplementation
L. Cebotaru1,2, W. Guggino2. 1Ophthalmology, Johns Hopkins University,
Baltimore, MD, USA; 2Physiology, Johns Hopkins University, Baltimore, MD, USA
A455E-CFTR is associated with milder forms of CF. Previous studies have shown
that the single channel properties of A455E are normal but that reduced processing
of the mutant channel is the likely cause of the mild disease phenotype (Sheppard
et. al. EMBO Journal, 14:876–883, 1995). Given that A455E is within NBD1 and is
a partial processing mutant we asked whether band C of A455E could be rescued
similar to DF508-CFTR. To address this question we expressed A455E in Cos7
cells and observed that the steady state levels of band C were higher than observed
for DF508-CFTR but lower than wt CFTR consistent with A455E being a partial
processing mutant. Interestingly, A455E was strongly temperature sensitive, because
growing cells at 27ºC has a large effect on increasing bands B and C. Steady state
levels of band C of A455E were increased by treating cells with the proteasome
inhibitors MG132 and PS341 suggesting that A455E is degraded in the proteasome.
Treating cells with cycloheximide demonstrated that the half life of A455E is much
longer than that of DF508-CFTR but less than wild type CFTR. Importantly, the
corrector 4A (Pedemonte et. al. JCI, 115:2564–2571, 2005) also increased the steady
state levels of bands B and C. We showed previously that a truncated form of
CFTR, D264-CFTR, can rescue DF508-CFTR. Cotransfection with D264-CFTR
also increased band C of A455E by transcomplementation. These results suggest
that partial trafﬁcking mutants of CFTR may also be likely candidates for small
molecule corrector and gene therapies.
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